Humacyte, Inc. Study: Novel Human-Derived ''Blood Vessels’’ Durable in Vivo and Off-the-Shelf

ORLANDO, Fla.--(BUSINESS WIRE)--Humacyte announced today that data presented at the American Heart Association Scientific Sessions demonstrates the longevity and durability of acellular arterial bypass grafts. Company scientists, working with researchers at Eastern Carolina Heart Institute, showed the potential for the naturally-derived vascular devices to provide a commercially viable solution for patients requiring vascular replacement or vascular access.